Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
enGene Holdings Inc. Warrants (ENGNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ENGNW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.28% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.39 | 52 Weeks Range 0.42 - 2.74 | Updated Date 06/22/2025 |
52 Weeks Range 0.42 - 2.74 | Updated Date 06/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.35% | Return on Equity (TTM) -33.97% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 26066719 |
Shares Outstanding - | Shares Floating 26066719 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
enGene Holdings Inc. Warrants
Company Overview
History and Background
enGene Holdings Inc. is a clinical-stage biotechnology company developing gene therapies. The warrants are derivative securities giving the holder the right to purchase common stock under specific conditions. Specifics on the history of the warrants depends on their issuance date and terms, and is generally tied to financing activities.
Core Business Areas
- Gene Therapy Development: Focuses on developing and commercializing gene therapies for various diseases.
Leadership and Structure
Information about the leadership team and organizational structure would require access to company filings (e.g., SEC filings).
Top Products and Market Share
Key Offerings
- EG-70: enGene's lead product candidate is EG-70, an investigational DNA medicine immunotherapy being evaluated for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Clinical trials are ongoing. Market share data is not applicable as the product is still in clinical development. Competitors include FerGene (nadofaragene firadenovec-vflp) and Merck (Keytruda).
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing with increasing investment and regulatory approvals for innovative therapies.
Positioning
enGene is positioned as a clinical-stage company focused on developing innovative gene therapies for unmet medical needs. Its competitive advantage depends on the success of its clinical trials and the efficacy and safety profile of its products.
Total Addressable Market (TAM)
The TAM for gene therapies is substantial, projected to reach billions of dollars. enGene's position within this TAM depends on the specific diseases it targets and the success of its clinical programs.
Upturn SWOT Analysis
Strengths
- Novel Gene Therapy Platform
- Experienced Management Team
- Focus on Unmet Medical Needs
- Strong Intellectual Property Portfolio
Weaknesses
- Clinical Trial Risks
- Regulatory Hurdles
- High Development Costs
- Reliance on Third-Party Manufacturing
Opportunities
- Positive Clinical Trial Results
- Partnerships with Pharmaceutical Companies
- Expansion to New Disease Areas
- Accelerated Regulatory Approvals
Threats
- Competition from Other Gene Therapy Companies
- Adverse Safety Events in Clinical Trials
- Changes in Regulatory Landscape
- Patent Challenges
Competitors and Market Share
Key Competitors
- BMY
- MRK
- BLUE
Competitive Landscape
enGene faces competition from established pharmaceutical companies and other gene therapy developers. Its competitive advantage depends on the efficacy and safety profile of its EG-70 treatment and other pipeline candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D progress and clinical trial milestones.
Future Projections: Future growth depends on the success of clinical trials and potential regulatory approvals. Analyst estimates would provide specific growth projections.
Recent Initiatives: Recent initiatives include advancing the EG-70 clinical program and exploring new gene therapy targets.
Summary
enGene Holdings is a clinical-stage biotech company with a focus on gene therapies, especially EG-70 for bladder cancer. The company's success hinges on positive clinical trial outcomes and regulatory approvals, and its financial performance is dependent on its research and development progress. Key risks include competition, clinical trial setbacks, and regulatory hurdles. The warrants' value derives directly from the underlying common stock value and thus is also dependent on the company's performance.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. The information is subject to change without notice. Investment in warrants involves significant risk, including the potential loss of principal.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About enGene Holdings Inc. Warrants
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2023-11-01 | President, CEO & Director Mr. Ronald H. W. Cooper | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://www.engene.com |
Full time employees 56 | Website https://www.engene.com | ||
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.